Legal basis: Article 16 of the Drug Administration Law of People's Republic of China (PRC) supports drug innovation that is oriented by clinical value and has definite or special curative effect on human diseases, encourages the development of new drugs with new treatment mechanism and multi-target system regulation and intervention on serious life-threatening diseases or rare diseases, and promotes the progress of drug technology.
The state encourages the use of modern science and technology and traditional Chinese medicine research methods to carry out scientific and technological research and drug development of traditional Chinese medicine, establish and improve a technical evaluation system that conforms to the characteristics of traditional Chinese medicine, and promote the inheritance and innovation of traditional Chinese medicine.
The state takes effective measures to encourage the research and innovation of children's medication, supports the development of new varieties, dosage forms and specifications of children's medication that meet their physiological characteristics, and gives priority to the examination and approval of children's medication.